Category: Insulet Corp.
Insulet misses the mark with its 3rd-quarter sales and earnings results and tightens its revenue forecast for the rest of the year.
Insulet (NSDQ:PODD) fell short of Wall Street's expectations with its 3rd-quarter results, missing the mark for both sales and earnings and tightening its revenue outlook for the rest of 2013.
Insulet Corp. hires the former director of Clinical Research & Technology for the Sansum Diabetes Research Institute, Dr. Howard Zisser, as its 1st medical director.
Insulet (NSDQ:PODD) said it named Dr. Howard Zisser, the former clinical director of the Sansum Diabetes Research Institute, as its 1st medical director.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Insulet and Medtronic agree to a cross-licensing deal to settle a patent infringement lawsuit over insulin management technology, plus a payment to Medtronic that Insulet predicts will cost it $10 million.
Investors pressure Insulet shares after 1 analyst cites increased adverse event reports in an FDA database and rampant customer complaints, but another analyst finds that the uptick is "benign" due to a reporting change.
UPDATED Sept. 25 at 11:15 a.m. with Jefferies report on reporting change for adverse events involving OmniPod
Deerfield Capital Management agrees to pay nearly $2 million to the SEC for short-selling violations involving Insulet, Derma Sciences, TearLab and other life science stocks.
Adding to pricing pressures already dragging down the global medical device industry, concerns about corruption and price-fixing spur a Chinese probe into medtech costs.
The Chinese Commerce Ministry's anti-monopoly bureau is looking for information on pricing and operations at medical device makers within the country as well as from around the world, according to a Reuters report.
Local sources told the new service that concerns about local corruption and price-fixing may have spurred the survey, but a deputy director at the China Assn. for Medial Devices Industry told reporters that there hadn't been word of any official investigations into the sector.
Shares of Insulet Corp. soar today after the medical device company reports its 1st positive cash flow for the 2nd quarter and beats Wall Street by a penny.
Insulet (NSDQ:PODD) shares spiked today after the medical device company reported record revenues for the 2nd quarter and said it logged its 1st positive quarterly cash flow.